Literature DB >> 26787540

B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.

Bo Jiang1, Fen Liu2, ZhiHui Liu2, Ting Zhang2, Dong Hua3.   

Abstract

B7-H3, a member of the B7 family, has been reported to be highly expressed in colorectal cancer and is associated with poor prognosis and overall survival. In this study, we found that overexpression of B7-H3 protected SW80 and HCT8 cells from 5-fluorouracil (5-FU) using CCK-8 assays by inducing resistance to 5-FU chemotherapy. Further investigation has revealed elevated expression of thymidylate synthase (TS) and upregulation of the PI3-kinase (PI3K)/Akt pathway in B7-H3 overexpressing cells. The effects of B7-H3 on activation of the PI3K/Akt pathway and elevation of TS expression could be blocked by LY294002, a specific inhibitor of the PI3K signaling pathway. These results implied that B7-H3 can induce colorectal cancer cell resistance to 5-FU by increasing TS expression and PI3K/Akt/TS signaling and plays an important role during these processes. This study provides more proof concerning the non-immunology effect of B7 molecules, a reminder that both co-stimulatory or inhibitory effects and non-immunology effects should be devoted equal attention.

Entities:  

Keywords:  5-FU resistance; B7 molecules; B7-H3; Colon cancer; PI3K-Akt; Thymidylate synthase

Mesh:

Substances:

Year:  2016        PMID: 26787540     DOI: 10.1007/s13277-015-4740-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  51 in total

1.  B7‑H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer.

Authors:  Fen Liu; Ting Zhang; Shitao Zou; Bo Jiang; Dong Hua
Journal:  Mol Med Rep       Date:  2015-07-07       Impact factor: 2.952

2.  B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer.

Authors:  Vibeke Anett Ingebrigtsen; Kjetil Boye; Christina Tekle; Jahn Martin Nesland; Kjersti Flatmark; Oystein Fodstad
Journal:  Int J Cancer       Date:  2012-04-24       Impact factor: 7.396

3.  [Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].

Authors:  Hideyuki Ishida; Kazuo Shirakawa; Tomonori Ohsawa; Jun Sobajima; Yoichi Hayashi; Hiroshi Nakada; Masaru Yokoyama; Daijo Hashimoto
Journal:  Gan To Kagaku Ryoho       Date:  2005-11

4.  Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia.

Authors:  Yixin Hu; Xin Lv; Yujie Wu; Ji Xu; Lingling Wang; Weifeng Chen; Wei Zhang; Jianyong Li; Sujiang Zhang; Hongxia Qiu
Journal:  Hematology       Date:  2014-08-16       Impact factor: 2.269

5.  Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.

Authors:  Varun V Prabhu; Joshua E Allen; David T Dicker; Wafik S El-Deiry
Journal:  Cancer Res       Date:  2015-02-20       Impact factor: 12.701

Review 6.  The B7 family and cancer therapy: costimulation and coinhibition.

Authors:  Xingxing Zang; James P Allison
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

8.  Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Authors:  Sung-Hyun Kim; Hyuk-Chan Kwon; Sung Yong Oh; Dong Mee Lee; Suee Lee; Jong-Hoon Lee; Mee-Sook Roh; Dae-Cheol Kim; Ki-Jae Park; Hong-Jo Choi; Hyo-Jin Kim
Journal:  Am J Clin Oncol       Date:  2009-02       Impact factor: 2.339

9.  Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.

Authors:  N Maeda; K Yoshimura; S Yamamoto; A Kuramasu; M Inoue; N Suzuki; Y Watanabe; Y Maeda; R Kamei; R Tsunedomi; Y Shindo; M Inui; K Tamada; S Yoshino; S Hazama; M Oka
Journal:  Ann Surg Oncol       Date:  2014-02-22       Impact factor: 5.344

10.  B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma.

Authors:  Jinhua Wang; Kelly K Chong; Yoshitaka Nakamura; Linhda Nguyen; Sharon K Huang; Christine Kuo; Wang Zhang; Hua Yu; Donald L Morton; Dave S B Hoon
Journal:  J Invest Dermatol       Date:  2013-03-08       Impact factor: 8.551

View more
  13 in total

Review 1.  Programmed death ligand 1 signals in cancer cells.

Authors:  Anand V R Kornepati; Ratna K Vadlamudi; Tyler J Curiel
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 60.716

2.  Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Authors:  Curtis A Clark; Harshita B Gupta; Gangadhara Sareddy; Srilakshmi Pandeswara; Shunhua Lao; Bin Yuan; Justin M Drerup; Alvaro Padron; José Conejo-Garcia; Kruthi Murthy; Yang Liu; Mary Jo Turk; Kathrin Thedieck; Vincent Hurez; Rong Li; Ratna Vadlamudi; Tyler J Curiel
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

3.  B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration.

Authors:  Xiaomao Hu; Minxian Xu; Yangzhi Hu; Na Li; Lei Zhou
Journal:  Cell Biochem Biophys       Date:  2021-03-20       Impact factor: 2.194

4.  B7-H3 participates in the development of Asthma by augmentation of the inflammatory response independent of TLR2 pathway.

Authors:  Wenjing Gu; Xinxing Zhang; Yongdong Yan; Yuqing Wang; Li Huang; Meijuan Wang; Xuejun Shao; Zhengrong Chen; Wei Ji
Journal:  Sci Rep       Date:  2017-01-17       Impact factor: 4.379

5.  B7-H3 promotes gastric cancer cell migration and invasion.

Authors:  Yecheng Li; Xiaodong Yang; Yong Wu; Kui Zhao; Zhenyu Ye; Junjia Zhu; Xiaohui Xu; Xin Zhao; Chungen Xing
Journal:  Oncotarget       Date:  2017-05-13

6.  Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.

Authors:  Harshita B Gupta; Curtis A Clark; Bin Yuan; Gangadhara Sareddy; Srilakshmi Pandeswara; Alvaro S Padron; Vincent Hurez; José Conejo-Garcia; Ratna Vadlamudi; Rong Li; Tyler J Curiel
Journal:  Signal Transduct Target Ther       Date:  2016-12-23

7.  p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.

Authors:  Karine Flem-Karlsen; Christina Tekle; Tove Øyjord; Vivi A Flørenes; Gunhild M Mælandsmo; Øystein Fodstad; Caroline E Nunes-Xavier
Journal:  Sci Rep       Date:  2019-04-09       Impact factor: 4.379

Review 8.  Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).

Authors:  Jorge Augusto Borin Scutti
Journal:  Int J Oncol       Date:  2018-02-23       Impact factor: 5.650

9.  Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression.

Authors:  Chung-Yu Chen; Ying-Yin Chen; Jeremy J W Chen; Kuan-Yu Chen; Chao-Chi Ho; Jin-Yuan Shih; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang
Journal:  Oncotarget       Date:  2017-06-28

Review 10.  B7H3 As a Promoter of Metastasis and Promising Therapeutic Target.

Authors:  Peixin Dong; Ying Xiong; Junming Yue; Sharon J B Hanley; Hidemichi Watari
Journal:  Front Oncol       Date:  2018-07-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.